- Report
- October 2024
- 187 Pages
Global
From €3312EUR$3,545USD£2,802GBP
€3680EUR$3,939USD£3,113GBP
- Report
- September 2024
- 100 Pages
Global
From €5559EUR$5,950USD£4,702GBP
- Report
- March 2025
- 200 Pages
Global
From €4195EUR$4,490USD£3,549GBP
- Report
- May 2024
- 133 Pages
Global
From €6071EUR$6,499USD£5,136GBP
- Report
- May 2024
- 137 Pages
Global
From €6071EUR$6,499USD£5,136GBP
- Report
- November 2024
- 183 Pages
Global
From €4204EUR$4,500USD£3,556GBP
- Report
- March 2024
- 225 Pages
Global
From €7427EUR$7,950USD£6,283GBP
- Report
- April 2023
- 120 Pages
Global
From €4438EUR$4,750USD£3,754GBP
- Report
- February 2024
- 77 Pages
Global
From €3500EUR$4,013USD£3,065GBP
- Report
- April 2025
- 50 Pages
Global
From €2476EUR$2,650USD£2,094GBP
- Report
- April 2025
- 50 Pages
Global
From €2476EUR$2,650USD£2,094GBP
Topotecan is a chemotherapy drug used to treat small cell lung cancer (SCLC). It is a topoisomerase inhibitor, meaning it works by blocking the enzyme topoisomerase I, which is involved in DNA replication. Topotecan is typically used in combination with other drugs, such as cisplatin, to treat SCLC. It is also used to treat ovarian cancer and is sometimes used off-label to treat other types of cancer.
The topotecan market is highly competitive, with several major pharmaceutical companies offering the drug. The market is expected to grow in the coming years due to the increasing prevalence of SCLC and the need for more effective treatments.
Companies in the topotecan market include Pfizer, Novartis, Teva Pharmaceuticals, and Mylan. Show Less Read more
